Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of AR1001 over 52 weeks in participants with incipient Alzheimer's disease
THE AIM OF THIS STUDY IS TO FIND OUT WHETHER A NEW EXPERIMENTAL DRUG CALLED AR1001 CAN HELP PEOPLE WITH ALZHEIMER'S DISEASE AND TO TEST WHETHER IT IS SAFE TO GIVE TO PEOPLE. TO DO THIS, THE EFFECTS OF AR1001 IN PATIENTS WITH ALZHEIMER'S DISEASE WILL BE COMPARED WITH THOSE SEEN IN PATIENTS TREATED WITH A PLACEBO.
Technical Summary
- PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AR1001 FOR 52 WEEKS IN PARTICIPANTS WITH INCIPIENT ALZHEIMER'S DISEASE.
- Code EudraCT: -
- Protocol number: AR1001-ADP3-US01
- Promoter: Aribio Co., Ltd.
- Molecule/Drug: AR1001
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.